1. Japan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Kohjin Bio Co.,Ltd.

Kohjin Bio Co.,Ltd.

TTSE:177A
767.00
JPY
-7.00
(-0.90%)
6.19BMarket Cap
Nov 13Next Earn
Kohjin Bio Co.,Ltd.
TSE:177A
(Tokyo Stock Exchange)

Recent

price

767.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2022
2023
2024
2025
2026
TTM
JPY
787.06
1,138.77
1,145.28
1,032.17
966.24
- -
Revenue per Share
117.18
199.23
92.43
157.56
49.11
- -
Basic EPS, GAAP
111.55
-23.91
62.64
5.56
-54.96
- -
Free Cash Flow per Basic Share
6.75
10
19
11.56
23.97
- -
Dividend per Share
442.05
601.76
666.48
1,131.12
1,163.08
- -
Book Value per Share
440.86
600.89
665.88
1,125.78
1,159.37
- -
Tangible Book Value per Share
5
4
4
5
5
5
Basic Weighted Avg Shares
3,947
4,743
4,770
5,206
4,939
- -
Sales/Revenue/Turnover
24.56
26.72
12.51
19.04
6.92
- -
Operating Margin (%)
179
168
300
361
396
- -
Depreciation Expense
588
830
385
795
251
- -
Net Income, GAAP
36.27
33.31
39.43
21.72
24.45
- -
Effective Tax Rate (%)
14.89
17.5
8.07
15.27
5.08
- -
Profit Margin (%)
1,236
457
1,012
2,580
1,899
- -
Working Capital
1,099
15
767
685
488
- -
LT Debt
2,217
3,018
3,342
5,782
5,945
- -
Total Equity
- -
16.79
6.43
10.96
3.14
- -
Return on Invested Capital (%)
- -
17.81
7.3
11.71
3.43
- -
Return on Capital (%)
- -
31.7
12.11
17.42
4.28
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
1,650
1,704
- -
LT Borrowings
300
225
- -
LT Finance Leases
- -
263
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5
5
5
Market Capitalization
7,974
6,185
4,554

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
4,638
4,268
- -
Cash, Cash Equivalents & STI
2,588
2,486
- -
Accounts Receivable, Net
789
562
- -
Inventories
878
872
- -
Total Current Liabilities
2,335
2,369
- -
Payables & Accruals
- -
- -
- -
ST Debt
1,650
1,704
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
2.83%
Free Cash Flow
- -
- -
-1,101.42%
Net Income, GAAP
- -
- -
-68.42%
Sales/Revenue/Turnover
- -
- -
-5.13%
Total Cash Common Dividend
- -
- -
110.15%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
5,206
2026
- -
- -
- -
- -
4,939
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
157.56
2026
- -
- -
- -
- -
49.11
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
11.56
2026
- -
- -
- -
- -
23.97
2027
- -
- -
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Kohjin Bio Co., Ltd. Kohjin Bio Co., Ltd. (177A.T) manufactures and sells biotechnology products including animal blood and sera; tissue culture media such as serum-free media for regenerative medicine, immunotherapy research, virus and recombinant protein production, hybridoma, human lymphocyte culture, insect cell lines, normal human cells, ES cells, in-vitro fertilization and early embryo culture kits, supplements, cell separation solutions, physiological salt solutions, and research reagents; microbial testing products comprising agar media for microorganism tests like sheep blood agar, GC chocolate agar, gram positive cocci, gram negative bacteria, susceptibility testing, differential, anaerobic growth, fungal, tube, food-related sterilization test, E. coli and coliform bacteria, staphylococcus spp., bacillus cereus, vibrio parahaemolyticus, total viable cell count, campylobacter mediums; in-vitro diagnostic agents; cosmetics; laboratory animals; and medical equipment, with services encompassing animal immunization, antibody preparation, import/export operations, and contract cell processing for cancer immune cell therapy under the Regenerative Medicine Safety Act. The company, founded in 1981 and headquartered in Sakado-shi, Saitama, Japan, maintains branches in Tokyo, Nagoya, Osaka, and Fukuoka, with consolidated subsidiaries including En Bio’s Co., Ltd. in Tokyo, Kohjin-Bio Technology (Shanghai) Co., Ltd. in China, Kohjin Bio Holding (Hong Kong) Limited, and Ajinomoto Kohjin Bio Co., Ltd., a joint venture established in 2018 with Ajinomoto Co., Inc. to produce clinical-grade cell culture media. Recent developments include a 2024 contract with OrganTech for technology transfer and patent licensing related to artificial skin technology for organ regeneration research support; revenue growth to 5.21 billion yen in fiscal 2024, up 9.14% year-over-year; and ongoing expansion in regenerative medicine cell processing and biotechnology supply capabilities.